MeiraGTx Holdings (MGTX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

MeiraGTx Holdings (MGTX) overview

MeiraGTx Holdings (MGTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 81.4m and operating profit of USD -106m; the year-end share price was 7.95 USD and market capitalisation was USD 645m. MeiraGTx Holdings is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get MeiraGTx Holdings's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD -5.8mFY 2025
Share price7.95 USDFY 2025 year end
RevenueUSD 81.4mFY 2025
Operating profitUSD -106mFY 2025
Net earningsUSD -114mFY 2025
Market capitalisationUSD 645mFY 2025 year end

About MeiraGTx Holdings

MeiraGTx develops genetic medicines for inherited and other diseases, using targeted local delivery of genetic medicine candidates. Its programs include clinical-stage treatments for radiation-induced dry mouth, Parkinson’s disease, and retinal dystrophy. The company also develops gene regulation technology and provides internal manufacturing capabilities for viral vectors, plasmids, and quality-control testing to support its programs and third-party supply obligations.

Generate the MeiraGTx Holdings report

MeiraGTx Holdings is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for MeiraGTx Holdings and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on MeiraGTx Holdings

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.